Genialis’ Post

Are murine Fc gamma receptors (FcγRs) derailing your drug discovery? Discover how FcResolv® NOG mice are ensuring researchers don't miss out on promising candidates in antibody-based drug studies. Join us for a free webinar presented by Dr. Ditte Olsen that dives into the benefits and applications of these one-of-a-kind super immunodeficient mice. Secure your spot: https://bit.ly/3TRYGjJ

Last week Alligator Bioscience AB was granted the first US patent for #ATOR4066! 🚀 Today - you should check out BioStock - Connecting Innovation and Capital's article to discover the significance of securing this patent and learn more about the potential of our innovative CD40 agonist. Just follow the post link. 👉

We are really looking forward to this event beginning of March to discuss 🎤 the importance of MIC testing for preclinical development! Are you planning on being there to following the discussions and talks? See you there - in Basel on the 6th-7th of March. #clinicalpharmacology #clinicalstudies #experttalk #conference

OX40 AGONIST: REVVING UP IMMUNE ACTIVATION https://lnkd.in/gF6aVpG6

Designing and computational analyzing of chimeric long-lasting #GLP-1 receptor agonists for type 2 #diabetes

Vicore Pharma AB is pleased to announce its participation in the Pulmonary Fibrosis Foundation (PFF) Summit 2023 in Orlando, Florida, from November 9-11. The #PFF summit is the world's largest conference dedicated to pulmonary fibrosis (#PF) research and education, bringing together experts in the field and the community to delve into this disease. #Vicore will be sharing insights and presenting three posters on Thursday, November 9th at 5:00-8:00 PM EST, titled:   Interim analysis of AIR - a Phase 2a trial of C21 in individuals with Idiopathic pulmonary fibrosis (IPF), presented by Cecilia Ganslandt, Global Medical Director ASPIRE – a patient friendly trial evaluating whether C21 improves lung function in IPF, presented by Åsa Magnusson, Chief Commercial Officer A personalized treatment for anxiety and challenges of living with Pulmonary Fibrosis, presented by Jessica Shull, Director of DTx   Following the summit, the posters will be made available on our website, here: https://lnkd.in/exKB4KG3   Join the Vicore team, including Ahmed Mousa, Åsa Magnusson, Cecilia Ganslandt, Caroline Spearpoint, Ph.D, and Jessica Shull, at our booth to learn more about our efforts in unlocking the potential of a new class of drug candidates – Angiotensin II Type 2 Receptor Agonists (#ATRAGs), with the aim of stopping disease progression and restoring lung function.   #VicorePharma #PFFSummit2023 #PulmonaryFibrosis

The AMR Conference is just 4 weeks away 😊. Find out what the conference sessions will be about 👀 today with “Preclinical models to optimize translation to human”. This session will review novel preclinical models to enhance dose selection for clinical proof-of-concept studies, as well as discuss the importance/necessity for development of standard MIC tests versus alternatives at the preclinical development stage. Join our session chaired by Martin Everett, AUROBAC THERAPEUTICS and listen to: Caterina Bissantz, Roche on the importance of lung fluid binding in dose estimation, Christopher Darlow, University of Liverpool on a rabbit model of emergent resistance, Ian Morrissey, on the role of in vitro screening in relation to lead molecule selection and translation into the clinic, Coen van Hasselt, Universiteit Leiden on PKPD for non-traditional antimicrobials, Nicolas Tesse, SEPTEOS and Markus Zeitlinger, Medical University of Vienna will further discuss on the importance of MIC tests for preclinical development. Interested? You can register here => http://bit.ly/3Ijwy4x

In 2022, we formed a strategic partnership with @Sosei Heptares to bring together the complementary capabilities of Verily's Immune Profiler and Sosei Heptares' GPCR structure-based drug design platform to accelerate drug discovery. I’m excited to share that today, we announced a major research milestone together - the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early Drug Discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD). Going from target concepts to novel, validated biology on such a fast timeline is an exciting demonstration of the power the combined approaches that Sosei Heptares and Verily have brought together. Learn more: https://lnkd.in/gcTuFSPB

What a nice recap of what's going on in the 'inhibition of KRAS' world. https://lnkd.in/eVYBGsQK #cancerresearch #biomedicalresearch #clinicaltrials #clinicalresearch #medcomms #KRAS

The AMR Conference is only less than 4 weeks away 😊. Find out what the conference sessions will be about 👀 - today with “Preclinical models to optimize translation to human”: This session will review novel preclinical models to enhance dose selection for clinical proof-of-concept studies, as well as discuss the importance/necessity for development of standard MIC tests versus alternatives at the preclinical development stage.  Join our session chaired by Martin Everett, AUROBAC THERAPEUTICS and listen to: Caterina Bissantz, Roche on the importance of lung fluid binding in dose estimation Christopher Darlow, University of Liverpool on a rabbit model of emergent resistance Ian Morrissey, Antimicrobial Focus Ltd on the role of in vitro screening in relation to lead molecule selection and translation into the clinic Coen van Hasselt, Universiteit Leiden on PKPD for non-traditional antimicrobials Nicolas Tesse, SEPTEOS and Markus Zeitlinger, Medical University of Vienna will further discuss on the importance of MIC tests for preclinical development. Interested? You can register here: https://lnkd.in/eVW8JWBe